The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...

Patients are eligible if less than 65 years of age with an established diagnosis of diffuse cutaneous scleroderma and a modified Rodnan Skin Score (mRSS) 7 of >14 and any of the following: (1) ...

Skin thickening, usually measured using the modified Rodnan skin score (mRSS), is often used as a surrogate marker for internal organ manifestations of systemic sclerosis (SSc). However, data from ...

The scleroderma skin pinch test checks the thickness and elasticity of your skin. It can help doctors diagnose and monitor scleroderma, an autoimmune condition that causes inflammation and thickening ...

Mycophenolate mofetil (MMF, CellCept) was effective in halting rapidly progressive diffuse cutaneous systemic sclerosis (SSc), but a substantial percentage of patients experienced recurrences when the ...